Literature DB >> 34997546

Single-cell RNA profiling identifies diverse cellular responses to EWSR1/FLI1 downregulation in Ewing sarcoma cells.

Roxane Khoogar1,2, Fuyang Li2, Yidong Chen2,3, Myron Ignatius1,2, Elizabeth R Lawlor4, Katsumi Kitagawa1,2, Tim H-M Huang1, Doris A Phelps2, Peter J Houghton5,6.   

Abstract

BACKGROUND: The EWSR1/FLI1 gene fusion is the most common rearrangement leading to cell transformation in Ewing sarcoma (ES). Previous studies have indicated that expression at the cellular level is heterogeneous, and that levels of expression may oscillate, conferring different cellular characteristics. In ES the role of EWSR1/FLI1 in regulating subpopulation dynamics is currently unknown.
METHODS: We used siRNA to transiently suppress EWSR1/FLI1 expression and followed population dynamics using both single cell expression profiling, CyTOF and functional assays to define characteristics of exponentially growing ES cells and of ES cells in which EWSR1/FLI1 had been downregulated. Novel transcriptional states with distinct features were assigned using random forest feature selection in combination with machine learning. Cells isolated from ES xenografts in immune-deficient mice were interrogated to determine whether characteristics of specific subpopulations of cells in vitro could be identified. Stem-like characteristics were assessed by primary and secondary spheroid formation in vitro, and invasion/motility was determined for each identified subpopulation. Autophagy was determined by expression profiling, cell sorting and immunohistochemical staining.
RESULTS: We defined a workflow to study EWSR1/FLI1 driven transcriptional states and phenotypes. We tracked EWSR1/FLI1 dependent proliferative activity over time to discover sources of intra-tumoral diversity. Single-cell RNA profiling was used to compare expression profiles in exponentially growing populations (si-Control) or in two dormant populations (D1, D2) in which EWSR1/FLI1 had been suppressed. Three distinct transcriptional states were uncovered contributing to ES intra-heterogeneity. Our predictive model identified ~1% cells in a dormant-like state and ~ 2-4% cells with stem-like and neural stem-like features in an exponentially proliferating ES cell line and in ES xenografts. Following EWSR1/FLI1 knockdown, cells re-entering the proliferative cycle exhibited greater stem-like properties, whereas for those cells remaining quiescent, FAM134B-dependent dormancy may provide a survival mechanism.
CONCLUSIONS: We show that time-dependent changes induced by suppression of oncogenic EWSR1/FLI1 expression induces dormancy, with different subpopulation dynamics. Cells re-entering the proliferative cycle show enhanced stem-like characteristics, whereas those remaining dormant for prolonged periods appear to survive through autophagy. Cells with these characteristics identified in exponentially growing cell populations and in tumor xenografts may confer drug resistance and could potentially contribute to metastasis.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Dormancy; Drug resistance; EWSR1/FLI1; Ewing sarcoma; Heterogeneity; Machine learning; Prediction; Single-cell RNA-seq; Stress response; Survival

Mesh:

Substances:

Year:  2022        PMID: 34997546     DOI: 10.1007/s13402-021-00640-x

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  69 in total

1.  Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.

Authors:  E de Alava; A Panizo; C R Antonescu; A G Huvos; F J Pardo-Mindán; F G Barr; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 2.  Ewing sarcoma: prognostic criteria, outcomes and future treatment.

Authors:  Patrick J Leavey; Anderson B Collier
Journal:  Expert Rev Anticancer Ther       Date:  2008-04       Impact factor: 4.512

3.  EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.

Authors:  E de Alava; A Kawai; J H Healey; I Fligman; P A Meyers; A G Huvos; W L Gerald; S C Jhanwar; P Argani; C R Antonescu; F J Pardo-Mindan; J Ginsberg; R Womer; E R Lawlor; J Wunder; I Andrulis; P H Sorensen; F G Barr; M Ladanyi
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

4.  Risk of recurrence and survival after relapse in patients with Ewing sarcoma.

Authors:  Martin Stahl; Andreas Ranft; Michael Paulussen; Tobias Bölling; Volker Vieth; Stefan Bielack; Irene Görtitz; Gabriele Braun-Munzinger; Jendrik Hardes; Heribert Jürgens; Uta Dirksen
Journal:  Pediatr Blood Cancer       Date:  2011-03-25       Impact factor: 3.167

Review 5.  Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas.

Authors:  Alberto S Pappo; Uta Dirksen
Journal:  J Clin Oncol       Date:  2017-12-08       Impact factor: 44.544

6.  Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.

Authors:  P P Lin; R I Brody; A C Hamelin; J E Bradner; J H Healey; M Ladanyi
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

7.  Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

Authors:  Peter J Houghton; Christopher L Morton; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Jianrong Wu; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2010-07-01       Impact factor: 3.167

Review 8.  Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.

Authors:  Nathalie Gaspar; Douglas S Hawkins; Uta Dirksen; Ian J Lewis; Stefano Ferrari; Marie-Cecile Le Deley; Heinrich Kovar; Robert Grimer; Jeremy Whelan; Line Claude; Olivier Delattre; Michael Paulussen; Piero Picci; Kirsten Sundby Hall; Hendrik van den Berg; Ruth Ladenstein; Jean Michon; Lars Hjorth; Ian Judson; Roberto Luksch; Mark L Bernstein; Perrine Marec-Bérard; Bernadette Brennan; Alan W Craft; Richard B Womer; Heribert Juergens; Odile Oberlin
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

Review 9.  Medulloblastomics: the end of the beginning.

Authors:  Paul A Northcott; David T W Jones; Marcel Kool; Giles W Robinson; Richard J Gilbertson; Yoon-Jae Cho; Scott L Pomeroy; Andrey Korshunov; Peter Lichter; Michael D Taylor; Stefan M Pfister
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

10.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

View more
  4 in total

Review 1.  Epigenetic and Transcriptional Signaling in Ewing Sarcoma-Disease Etiology and Therapeutic Opportunities.

Authors:  Mingli Li; Chun-Wei Chen
Journal:  Biomedicines       Date:  2022-06-05

Review 2.  Pediatric Sarcomas: The Next Generation of Molecular Studies.

Authors:  Petros Giannikopoulos; David M Parham
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

Review 3.  Comparative characteristics of small cell lung cancer and Ewing's sarcoma: a narrative review.

Authors:  Gerhard Hamilton
Journal:  Transl Lung Cancer Res       Date:  2022-06

Review 4.  Regulation of Metastasis in Ewing Sarcoma.

Authors:  Mingli Li; Chunwei Chen
Journal:  Cancers (Basel)       Date:  2022-10-07       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.